Paramount Global Statistics
Total Valuation
HOOKIPA Pharma has a market cap or net worth of 11.17 million. The enterprise value is -28.51 million.
| Market Cap | 11.17M |
| Enterprise Value | -28.51M |
Important Dates
The next estimated earnings date is Monday, August 11, 2025.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HOOKIPA Pharma has 12.68 million shares outstanding. The number of shares has increased by 16.01% in one year.
| Current Share Class | 9.80M |
| Shares Outstanding | 12.68M |
| Shares Change (YoY) | +16.01% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 0.48% |
| Owned by Institutions (%) | 21.43% |
| Float | 9.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.19 |
| PB Ratio | 0.33 |
| P/TBV Ratio | 0.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.39 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.54 |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.61 |
| Quick Ratio | 2.92 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -105.79% and return on invested capital (ROIC) is -64.45%.
| Return on Equity (ROE) | -105.79% |
| Return on Assets (ROA) | -45.20% |
| Return on Invested Capital (ROIC) | -64.45% |
| Return on Capital Employed (ROCE) | -167.87% |
| Revenue Per Employee | 110,012 |
| Profits Per Employee | -862,506 |
| Employee Count | 87 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -106,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.89% in the last 52 weeks. The beta is 0.92, so HOOKIPA Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | -82.89% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 1.74 |
| Relative Strength Index (RSI) | 30.15 |
| Average Volume (20 Days) | 193,500 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.26 |
Income Statement
In the last 12 months, HOOKIPA Pharma had revenue of 9.35 million and -73.31 million in losses. Loss per share was -5.85.
| Revenue | 9.35M |
| Gross Profit | -50.47M |
| Operating Income | -74.90M |
| Pretax Income | -73.42M |
| Net Income | -73.31M |
| EBITDA | -72.40M |
| EBIT | -74.90M |
| Loss Per Share | -5.85 |
Balance Sheet
The company has 40.28 million in cash and 596,000 in debt, giving a net cash position of 39.68 million or 3.13 per share.
| Cash & Cash Equivalents | 40.28M |
| Total Debt | 596,000 |
| Net Cash | 39.68M |
| Net Cash Per Share | 3.13 |
| Equity (Book Value) | 34.08M |
| Book Value Per Share | 2.71 |
| Working Capital | 43.45M |
Cash Flow
In the last 12 months, operating cash flow was -52.77 million and capital expenditures -98,000, giving a free cash flow of -52.87 million.
| Operating Cash Flow | -52.77M |
| Capital Expenditures | -98,000 |
| Free Cash Flow | -52.87M |
| FCF Per Share | -4.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | -801.02% |
| Pretax Margin | -785.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HOOKIPA Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.01% |
| Shareholder Yield | n/a |
| Earnings Yield | -656.50% |
| FCF Yield | -473.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 10, 2024. It was a reverse split with a ratio of 0.1.
| Last Split Date | Jul 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
HOOKIPA Pharma has an Altman Z-Score of -11.57 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.57 |
| Piotroski F-Score | 1 |